Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3%
Jiangsu Hengrui Pharmaceuticals (SHA:600276) will conduct clinical trials on insulin aspart injection after receiving approval from China's National Medical Products Administration, according to the c
Why Jiangsu Hengrui Medicine's (SHSE:600276) Earnings Are Better Than They Seem
Despite posting healthy earnings, Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276 ) stock has been quite weak. We have done some analysis, and found some encouraging factors that we believe the sha
Haitong International: Free circuit with long slopes and heavy snow, domestic market space is expected to open up
The Zhitong Finance App learned that Haitong International released a research report saying that compared with innovative domestic drugs to replace relatively mature oncology drugs, self-exempt drugs also have the advantage of a large market size (suitable for the domestic pricing environment for new drugs). The differences are that patients are widely distributed (channel coverage is required), are more chronic diseases, and there is competition for traditional drugs (requiring fast efficacy and high accessibility). Combined with the current market financing environment, although the self-defense target layout is still crowded, companies with good cash flow will be more likely to obtain excess profits. It is recommended to pay attention to Hengrui Pharmaceutical (600276.SH), Kangzhe Pharmaceutical (00867), Sansheng Guojian (688)
Huayuan Securities released a research report on April 25 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) leading domestic pharmaceutical companies entering a new cycle of comprehensiv
Huayuan Securities released a research report on April 25 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) leading domestic pharmaceutical companies entering a new cycle of comprehensive innovation and transformation; 2) collection pressure has been basically adjusted; 3) the innovative R&D pipeline layout is comprehensive, or welcoming a new harvest period. (Mainichi Keizai Shimbun)
Hengrui Pharmaceutical's 2023 performance rebounded steadily, and the sales expense ratio declined year-on-year
On the evening of April 17, Hengrui Pharmaceutical released its 2023 annual report. In 2023, Hengrui Pharmaceutical achieved operating income of 22.82 billion yuan, up 7.26% year on year, net profit attributable to shareholders of listed companies of 4.302 billion yuan, up 10.14% year on year, deducted non-net profit attributable to shareholders of listed companies of 4.141 billion yuan, up 21.46% year on year, net operating cash flow of 7.644 billion yuan, a sharp increase of 504.12% year on year. According to the report's analysis, as Hengrui Pharmaceutical's innovative achievements continue to be approved, the clinical value of innovative drugs is highlighted, driving revenue growth. 2023
Express News | Hengrui Pharmaceutical: Obtained the Notice of Approval for Clinical Trials of Medon Insulin Injection Drugs
Hengrui Pharmaceutical (600276): The share of innovative drug revenue continues to increase, and the internationalization process is progressing steadily
Key investment events: The company released its 2023 annual report, achieved revenue of 22.82 billion yuan in 2023 (+7.26%, year-on-year growth rate in parentheses, same below); achieved net profit of 4.302 billion yuan (+10.1)
Dongwu Securities released a research report on April 24 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) continuous implementation of innovative results, driving steady growth in perfo
Dongwu Securities released a research report on April 24 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) continuous implementation of innovative results, driving steady growth in performance; 2) continuous overseas licensing and overseas clinical gains to steadily advance the internationalization process; 3) early R&D capabilities are outstanding, and multiple innovative technology platforms are expected to continuously produce new products. (Mainichi Keizai Shimbun)
Hengrui Pharmaceutical (600276): Stable performance and continuous growth in revenue from innovative drugs
Revenue growth is steady, and innovative drugs continue to be released. The company's total revenue in 2023 was $22.82 billion (+7.26%). The main business is the pharmaceutical manufacturing industry's revenue of 22.377 billion yuan (+5.49%), of which innovative drugs include tax
Beishui added nearly HK$400 million each to Tencent and the Hong Kong Stock Exchange, selling Meituan for nearly HK$500 million; Nanshui bought Zijin Mining for nearly HK$500 million
On April 23 (Tuesday), Nanxia Capital made a net purchase of HK$2.34 billion in Hong Kong stocks today, and the Bank of China received a net purchase of HK$696 million.
Pharmaceutical stocks continued to rise in the afternoon. Osecon moved up the market. BeiGene Shenzhou and Hengrui Pharmaceuticals both rose more than 4%, and the weights of the pharmaceutical industry such as Kangde, Aier Ophthalmology, and Mindray Healt
Pharmaceutical stocks continued to rise in the afternoon. Osecon moved up the market. BeiGene Shenzhou and Hengrui Pharmaceuticals both rose more than 4%, and the weights of the pharmaceutical industry such as Kangde, Aier Ophthalmology, and Mindray Healthcare collectively strengthened.
Hengrui?? Medicine (600276): Innovative drugs drive performance growth and lead the development of the innovative pharmaceutical industry
Incident: 1) The company released its 2023 annual report, achieving operating income of 22.82 billion yuan, +7.26% year over year; net profit to mother of 4.302 billion yuan, +10.14% year over year; net profit excluding non-return to mother 41.41
Hengrui Pharmaceutical (600276) Review Report: Revenue from innovative drugs is growing steadily, R&D and internationalization are accelerating
Event: On April 18, 2024, Hengrui Pharmaceutical released the 2023 Annual Report and the 2024 First Quarter Report. The company achieved revenue of 22.82 billion yuan in 2023, an increase of 7.26% over the previous year;
Hengrui Pharmaceutical (600276.SH) subsidiary obtains drug clinical trial approval notice
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, Suzhou Shengdia Biomedical Co., Ltd., a subsidiary of the company, received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for injectable carelizumab and will conduct clinical trials in the near future. Injectable carelizumab has been approved for nine domestic indications, namely: approved in May 2019 for the treatment of recurrent or refractory classic Hodgkin lymphoma that has undergone at least second-line systemic chemotherapy; in March 2020, it was approved for previous use of sorafil
Express News | Hengrui Pharmaceutical: injectable carelizumab received a notice of approval for clinical trials of the drug
China Galaxy released a research report on April 22 stating that Hengrui Pharmaceutical (600276.SH) was given a recommended rating. The main reasons for the rating include: 1) continuous implementation of innovative achievements to drive steady revenue gr
China Galaxy released a research report on April 22 stating that Hengrui Pharmaceutical (600276.SH) was given a recommended rating. The main reasons for the rating include: 1) continuous implementation of innovative achievements to drive steady revenue growth; 2) continuous construction of leading technology platforms to create high-quality innovative products. (Mainichi Keizai Shimbun)
Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) shareholders are probably feeling a little disappointed, since its shares fell 5.5% to CN¥41.68 in the week after its latest quarterly results. T
Southwest Securities released a research report on April 21 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) steady improvement in performance and profitability; 2) continuous approval
Southwest Securities released a research report on April 21 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) steady improvement in performance and profitability; 2) continuous approval of innovative achievements, driving steady growth in overall performance; 3) continuing to build industry-leading new technology platforms to strengthen innovation at the source. (Mainichi Keizai Shimbun)
Hengrui Pharmaceutical (600276): Performance is in line with expectations, focus on innovative drug sales and pipeline progress
The results for '23 and 1Q24 are in line with our and market expectations. The company announced 2023 and 1Q24 results: 2023 revenue of $22.82 billion (+7.3% YoY), net profit of $4.30 billion to mother
Hengrui Pharmaceutical (600276) Review: Innovative drugs break through the 10 billion mark and continue to innovate and upgrade
Investment highlights: Event: The company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved operating income of 22.82 billion yuan (+7.26% YoY) and realized net profit of 4.302 billion yuan (same period)
No Data